biostudies-literatureUnknown12(4)Bajpai M<h4>Importance</h4>No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.<h4>Objective</h4>To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients.<h4>Design, setting and participants</h4>A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group.<h4>Intervention</h4>One group received COPLA with SMT (n=200), and another group received SMT only (n=200).<h4>Main outcome measures</h4>Primary oBMJ opene055189https://www.ebi.ac.uk/biostudies/studies/S-EPMC8987237biostudies-literatureEfficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).PMC8987237Jain SBharti PAgarwal RAgarwal SShankar PBhardwaj AYadav BKKumar SSaluja VSarin SKMaheshwari AGupta AThomas SSDogra VNarayanan AKumar GGupta EChhabra KTrehanpati NBajpai MHussain JBihari CKale PfalseEfficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial).<h4>Importance</h4>No proven treatment is available for severely ill COVID-19. Therapeutic use of COVID-19 convalescent plasma (COPLA) is under investigation.<h4>Objective</h4>To compare the efficacy of COPLA with standard medical therapy (SMT) alone in severe COVID-19 patients.<h4>Design, setting and participants</h4>A multicentric, open-labelled, phase-III randomised controlled trial conducted at two treatment centres with COPLA collected at the third dedicated centre in North-India, the coordinating centre during trial from June 2020 to December 2020. The study population comprised 400 participants in the ratio of 1:1 in each treatment group.<h4>Intervention</h4>One group received COPLA with SMT (n=200), and another group received SMT only (n=200).<h4>Main outcome measures</h4>Primary o2022-01-01T00:00:00Z2022 Apr2026-05-09T15:35:07.359Z2025-04-19T21:47:55.978ZS-EPMC89872373538781310.1136/bmjopen-2021-055189